Valuation: Aprogen Biologics Inc.

Market Cap	27.4B 18.42M 16.1M 14.86M 13.69M 25.81M 1.77B 26.39M 178M 69.85M 869M 69.19M 67.67M 2.99B	P/E 2024	-0.79x	P/E 2025	-0.6x
Enterprise Value	205B 138M 120M 111M 102M 193M 13.25B 197M 1.33B 522M 6.49B 517M 505M 22.34B	EV / Sales 2024	3.66x	EV / Sales 2025	3.82x
Free-Float	95.86%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : Aprogen Biologics Inc.

07-13	Aprogen Biologics Inc. announced that it expects to receive KRW 2.000000772 billion in funding from Aprogen, Inc.	CI
06-30	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-28	Aprogen Biologics Inc. announced that it has received KRW 10 billion in funding from Aprogen, Inc.	CI
05-20	Aprogen Biologics Inc. announced that it expects to receive KRW 10 billion in funding from Aprogen, Inc.	CI
05-14	Aprogen Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-27	Aprogen Biologics Inc. announced that it has received KRW 2.000001375 billion in funding from Aprogen, Inc.	CI
04-12	Aprogen Biologics Inc. announced that it expects to receive KRW 2.000001375 billion in funding from Aprogen, Inc.	CI
03-20	Aprogen Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-13	Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
23/10/25	Aprogen Biologics Inc. announced that it has received KRW 15 billion in funding from APTN Inc.	CI
15/10/25	Aprogen Biologics Inc. announced that it expects to receive KRW 15 billion in funding from APTN Inc.	CI
13/08/25	Aprogen Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
21/05/25	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI

More news

News in other languages: Aprogen Biologics Inc.

23/11/20	MÄRKTE ASIEN/Kräftige Gewinne in Seoul und Schanghai - Tokio pausiert
23/11/20	MÄRKTE ASIEN/Aufwärts mit Impfstoff-Optimismus

More news

Managers and Directors: Aprogen Biologics Inc.

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	31/03/2012
Jae-Seob Kim CEO	Chief Executive Officer	63	12/10/2023
Jong-Soo Kang SAM	Sales & Marketing	62	-

Director	Title	Age	Since
Jung-Chool Kim BRD	Director/Board Member	70	31/03/2012
Dong-Chul Shin BRD	Director/Board Member	65	22/03/2020
Jae-Seob Kim BRD	Director/Board Member	63	12/10/2023

More insiders

Aprogen Biologics Inc, formerly Aprogen Pharmaceuticals Inc, is a Korea-based company principally engaged in the pharmaceutical business. The Company operates its business through two segments. The Medicine Business segment is engaged in the manufacture and sale of central nervous system drugs, autonomic agents, arteriosclerosis agents, metabolic agents, circulatory system drugs, biopharmaceuticals and others. The Segment is also engaged in the manufacture and sale of cosmetics such as skin moisturizers and others. The Gaming Business segment is engaged in the development and operation of role-playing games (RPGs).

Employees

379

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
16/07/26	₩2,080.00	0.00%	71,517
15/07/26	₩2,080.00	+4.26%	56,623
14/07/26	₩1,995.00	+0.76%	45,712
13/07/26	₩1,980.00	-5.04%	68,646
10/07/26	₩2,085.00	+4.25%	46,532

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 16/07/2026			5-day change	1st Jan Change
2,080.00 ^KRW	0.00%		-0.24%	-73.28%

1 week	-0.24%
Current month	+0.73%
1 month	-8.17%
3 months	-44.75%
6 months	-71.93%
Current year	-73.28%

1 week	1,910	2,155
1 month	1,869	2,250
Current year	1,869	8,490
1 year	1,869	10,395
3 years	1,869	108,600
5 years	1,869	204,750
10 years	1,869	1,000,000

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/06/24	Jung-Chool Kim	Expiration	Chief Executive Officer	21,884	0.0164%
28/06/24	Sung Nao	Fiscal year		1,180	0.0009%
28/06/24	Yong-woo Kim	Fiscal year		1,282	0.0010%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APROGEN BIOLOGICS INC.	0.00%	-0.24%	-78.96%	-95.89%	18.42M
ELI LILLY AND COMPANY	+0.85%	-0.80%	+52.79%	+161.33%	1,051B
JOHNSON & JOHNSON	+1.23%	-1.53%	+54.58%	+59.08%	609B
ABBVIE INC.	+0.04%	+2.58%	+34.47%	+86.33%	450B
ROCHE HOLDING AG	+0.78%	-0.71%	+29.28%	+24.10%	330B
NOVARTIS AG	+1.41%	+0.58%	+35.44%	+40.67%	284B
ASTRAZENECA PLC	-0.27%	-1.87%	+22.34%	+22.51%	263B
NOVO NORDISK A/S	-1.76%	+2.37%	-20.43%	-38.00%	223B
AMGEN INC.	-1.42%	+0.80%	+24.27%	+57.50%	198B
GILEAD SCIENCES, INC.	-1.48%	+3.43%	+24.08%	+71.67%	167B
Average	-0.06%	+0.46%	+17.79%	+38.93%	357.51B
Weighted average by Cap.	+0.37%	+0.02%	+37.51%	+79.63%

Aprogen Biologics Inc. Share Price

Stocks

A003060

KR7003060001

Pharmaceuticals

Valuation: Aprogen Biologics Inc.

Chart: Aprogen Biologics Inc.

Latest news : Aprogen Biologics Inc.

News in other languages: Aprogen Biologics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Aprogen Biologics Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

	2024	2025
Net sales	67.38B 45.31M 39.6M 36.54M 33.68M 63.48M 4.36B 64.89M 437M 172M 2.14B 170M 166M 7.36B	73.23B 49.24M 43.03M 39.71M 36.6M 68.99M 4.74B 70.52M 475M 187M 2.32B 185M 181M 8B
Net income	-105B -70.6M -61.7M -56.93M -52.48M -98.91M -6.8B -101M -680M -268M -3.33B -265M -259M -11.46B	-170B -115M -100M -92.37M -85.14M -160M -11.03B -164M -1.1B -434M -5.4B -430M -421M -18.6B
Net Debt	116B 77.81M 68M 62.74M 57.83M 109M 7.49B 111M 750M 295M 3.67B 292M 286M 12.63B	177B 119M 104M 96.08M 88.56M 167M 11.47B 171M 1.15B 452M 5.62B 447M 438M 19.34B